Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: Report of three cases

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 999-1002

  El Saghir, Nagi S ^a   El Hajj, Ihab I ^a   Makarem, Jawad A ^a   Otrock, Zaher K ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Aromatase inhibition; Hormone receptor positive; Metastatic breast cancer; Ovarian ablation; Premenopause

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE RECEPTOR; MEGESTROL ACETATE; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADULT; ANAMNESIS; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; MASTECTOMY; METASTASIS; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; SCLEROSIS; SPINE METASTASIS; TREATMENT OUTCOME; VERTEBRA BODY; VITAMIN SUPPLEMENTATION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OVARIECTOMY; OVARY; PREMENOPAUSE; RECEPTORS, STEROID; TRIAZOLES;

EID: 33748467642     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224456.28898.37     Document Type: Article

References (15)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-2442.
2. de Ziegler D, Mattenberger C, Luyet C, Romoscanu I, Irion NF, Bianchi-Demicheli F. Clinical use of aromatase inhibitors (AI) in premenopausal women. J Steroid Biochem Mol Biol 2005; 95:121-127.
3. Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004; 9:507-517.
4. Counsell R, Bain G, Williams MV, Dixon AK. Artificial radiation menopause: where are the ovaries? Clin Oncol (R Coll Radiol) 1996; 8:250-253.
5. Buzzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, et al. Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. Br J Cancer 1995; 71:1111-1114.
6. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined hormone agents trialists' group and the European organization for research and treatment of cancer: combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19:343-353.
7. Blamey RW, EUSOMA. Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer 2002; 38:615-634.
8. Jonat W, Hilpert F. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. J Cancer Res Clin Oncol 2006; 132:343-355.
9. Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62:679-683.
10. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992; 43:155-159.
11. Celio L, Martinetti A, Ferrari L, Buzzoni R, Mariani L, Miceli R, et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999; 19:2261-2268.
12. Hisamatsu K, Iwamori S, Minami K, Tanabe K, Ota K, Akiyama H. A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist. Gan To Kagaku Ryoho 1997; 24:1327-1330.
13. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004; 90:590-594.
14. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 2005; 93(Suppl 1):S16-S22.
15. SOFT/TEXT/PERCHE (STP trials). Available at: http://www.ibcsg.org/public/ general_pages/trials/open/pub_trials_open.shtml.